NO973933L - Vaskulær endotelvekstfaktor B - Google Patents

Vaskulær endotelvekstfaktor B

Info

Publication number
NO973933L
NO973933L NO973933A NO973933A NO973933L NO 973933 L NO973933 L NO 973933L NO 973933 A NO973933 A NO 973933A NO 973933 A NO973933 A NO 973933A NO 973933 L NO973933 L NO 973933L
Authority
NO
Norway
Prior art keywords
vascular endothelial
polypeptides
growth factor
endothelial growth
vegf
Prior art date
Application number
NO973933A
Other languages
English (en)
Norwegian (no)
Other versions
NO973933D0 (no
Inventor
Ulf Eriksson
Birgitta Olofsson
Kari Alitalo
Katri Pajusola
Original Assignee
Ludwig Inst Cancer Res
Helsingfors University Licensi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973933(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/469,427 external-priority patent/US5607918A/en
Application filed by Ludwig Inst Cancer Res, Helsingfors University Licensi filed Critical Ludwig Inst Cancer Res
Publication of NO973933D0 publication Critical patent/NO973933D0/no
Publication of NO973933L publication Critical patent/NO973933L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO973933A 1995-03-01 1997-08-27 Vaskulær endotelvekstfaktor B NO973933L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39765195A 1995-03-01 1995-03-01
US08/469,427 US5607918A (en) 1995-03-01 1995-06-06 Vascular endothelial growth factor-B and DNA coding therefor
US08/569,063 US5928939A (en) 1995-03-01 1995-12-06 Vascular endothelial growth factor-b and dna coding therefor
PCT/US1996/002957 WO1996026736A1 (en) 1995-03-01 1996-03-01 Vascular endothelial growth factor-b

Publications (2)

Publication Number Publication Date
NO973933D0 NO973933D0 (no) 1997-08-27
NO973933L true NO973933L (no) 1997-09-01

Family

ID=27410265

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973933A NO973933L (no) 1995-03-01 1997-08-27 Vaskulær endotelvekstfaktor B

Country Status (14)

Country Link
US (5) US5928939A (de)
EP (1) EP0814827B1 (de)
JP (2) JP3275024B2 (de)
CN (1) CN1146440C (de)
AT (1) ATE245437T1 (de)
AU (1) AU741856B2 (de)
CA (1) CA2211687C (de)
DE (1) DE69629181T2 (de)
DK (1) DK0814827T3 (de)
ES (1) ES2202432T3 (de)
NO (1) NO973933L (de)
NZ (1) NZ305091A (de)
PT (1) PT814827E (de)
WO (1) WO1996026736A1 (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
ATE309360T1 (de) 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
HU223438B1 (hu) * 1995-03-02 2004-07-28 Amrad Operations Pty. Ltd. Új növekedési faktor és ezt kódoló génszekvencia
US7160991B1 (en) 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
EP0873348A4 (de) * 1995-06-06 2000-11-08 Human Genome Sciences Inc Menschlicher vaskularer endothelialer wachtumsfaktor 3
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
ES2239338T5 (es) 1995-09-29 2013-05-31 Vegenics Pty Ltd Genes regulados y sus usos
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor
JP2000516478A (ja) * 1996-12-20 2000-12-12 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ Ｖｅｇｆ−ｂ／受容体複合体およびその利用方法
AU6691098A (en) 1997-03-07 1998-09-22 Wistar Institute Of Anatomy & Biology, The Method and compositions for healing tissue defects and inducing hypervascularityin mammalian tissue
CN1260835A (zh) * 1997-04-25 2000-07-19 科莱特诺医疗公司 截短的vegf相关蛋白质
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
WO1999040197A2 (en) 1998-02-06 1999-08-12 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
DK1129110T3 (da) 1998-11-10 2010-04-06 Ludwig Inst Cancer Res Blodpladeafledt vækstfaktor D, DNA kodende derfor og anvendelser deraf
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
JP2002535006A (ja) * 1999-01-29 2002-10-22 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ 血小板由来増殖因子／血管内皮増殖因子様増殖因子ｈとその利用法
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
EP1166102A4 (de) * 1999-03-03 2002-08-21 Ludwig Inst Cancer Res Herzfehler von vegf-defizienten tieren und entsprechende verfahren
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
AU781470B2 (en) * 1999-06-07 2005-05-26 Baxter Aktiengesellschaft Targeted angiogenesis
BR0012793A (pt) * 1999-07-28 2002-04-30 Univ Leland Stanford Junior Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
CA2399790C (en) * 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
AUPQ568100A0 (en) * 2000-02-16 2000-03-09 Amrad Operations Pty. Limited A method for producing recombinant molecules
US6965010B2 (en) * 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP1282723A4 (de) * 2000-05-17 2007-11-21 Ludwig Inst Cancer Res Verfahren zum nachweis der anwesenheit von tumorzellen und zum screenen nach anti-tumormedikamenten
CN1461342A (zh) * 2000-07-26 2003-12-10 路德维格癌症研究所 糖基化vegf－b和增加可溶性vegf－b量的方法
CN1211126C (zh) * 2000-08-04 2005-07-20 人体基因组科学有限公司 血管内皮生长因子2
WO2002029087A2 (en) * 2000-10-02 2002-04-11 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
EP1330252A4 (de) * 2000-11-01 2007-12-26 Ludwig Inst Cancer Res In-vivo-stimulierung der angiogenen aktivität
EP1341914A2 (de) * 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation der angiogenese durch zinkfinger-proteine
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20070050857A1 (en) * 2001-02-28 2007-03-01 Hayward Nick K Method of treatment and prophylaxis
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20030170786A1 (en) * 2001-04-13 2003-09-11 Rosen Craig A. Vascular endothelial growth factor 2
WO2002083704A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050043227A1 (en) * 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
CA2451311A1 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2447851C (en) * 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
AU2002331669A1 (en) 2001-08-23 2003-03-10 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
CA2429483A1 (en) * 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
EP1912069A3 (de) 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Verfahren für Schirmliganden mit eukaryotischer Zellenanzeige
WO2003104415A2 (en) * 2002-06-05 2003-12-18 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US20030232439A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
EP1517921B1 (de) * 2002-06-28 2006-06-07 Domantis Limited Dual-specifische liganden mit erhöhter halbwertszeit
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004009773A2 (en) 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US20040258670A1 (en) * 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
EP1578801A2 (de) * 2002-12-27 2005-09-28 Domantis Limited Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP1560025A3 (de) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Marker spezifisch für Diabetes
EP2286791B1 (de) 2003-12-30 2014-03-26 Durect Corporation Polymereimplantate, welche vorzugsweise ein Gemisch von PEG und PLG enthalten, für kontrollierte Freisetzung von Wirkstoffen
EP1729750A2 (de) * 2004-03-02 2006-12-13 The Ludwig Institute for Cancer Research Verfahren zur hemmung der tumorbildung und des tumorwachstums
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
JP4903689B2 (ja) * 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
DK1781321T3 (da) * 2004-08-02 2014-04-14 Zenyth Operations Pty Ltd Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
US7358085B2 (en) * 2005-02-28 2008-04-15 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
AU2006235489A1 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
DE602006020881D1 (de) 2005-08-15 2011-05-05 Vegenics Pty Ltd Enen eigenschaften
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
DK2548578T3 (da) 2006-05-17 2014-10-06 Ludwig Inst Cancer Res Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
US7819579B2 (en) * 2007-11-26 2010-10-26 Schmulenson Harold K Radiation sensing device and holder
WO2009075565A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
EP2271365A4 (de) * 2008-04-09 2011-10-26 Ludwig Inst Cancer Res Regulierung von fettsäuretransportern
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
RU2477529C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
EA201690212A8 (ru) 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний
CA2932465C (en) * 2013-12-18 2023-08-22 Csl Limited Methods of treating wounds in a diabetic subject
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
US10745454B2 (en) * 2018-01-31 2020-08-18 Seyed Mohsen Asghari Method of synthesizing antagonist peptides for cell growth
CN109337931A (zh) * 2018-11-02 2019-02-15 东北师范大学 Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
CN110777146A (zh) * 2019-11-28 2020-02-11 南通大学 一种pdgfb启动子活性报告质粒的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
ATE309360T1 (de) * 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
HU223438B1 (hu) * 1995-03-02 2004-07-28 Amrad Operations Pty. Ltd. Új növekedési faktor és ezt kódoló génszekvencia
EP0873348A4 (de) * 1995-06-06 2000-11-08 Human Genome Sciences Inc Menschlicher vaskularer endothelialer wachtumsfaktor 3

Also Published As

Publication number Publication date
EP0814827B1 (de) 2003-07-23
EP0814827A1 (de) 1998-01-07
JPH10510718A (ja) 1998-10-20
US6331301B1 (en) 2001-12-18
EP0814827A4 (de) 1999-11-10
CA2211687C (en) 2011-05-24
WO1996026736A1 (en) 1996-09-06
US20050064493A1 (en) 2005-03-24
US7341996B2 (en) 2008-03-11
NO973933D0 (no) 1997-08-27
CN1146440C (zh) 2004-04-21
US20030170253A1 (en) 2003-09-11
AU741856B2 (en) 2001-12-13
JP3275024B2 (ja) 2002-04-15
CN1176603A (zh) 1998-03-18
ES2202432T3 (es) 2004-04-01
DK0814827T3 (da) 2003-11-10
DE69629181T2 (de) 2004-05-13
HK1008485A1 (en) 1999-07-30
US5928939A (en) 1999-07-27
DE69629181D1 (de) 2003-08-28
JP3297687B2 (ja) 2002-07-02
ATE245437T1 (de) 2003-08-15
PT814827E (pt) 2003-11-28
NZ305091A (en) 1998-11-25
JP2000228982A (ja) 2000-08-22
US5840693A (en) 1998-11-24
AU5302196A (en) 1996-09-18
CA2211687A1 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
NO973933D0 (no) Vaskulær endotelvekstfaktor B
DK1749836T3 (da) Rekombinant vaskulær endothelcellevækstfaktor D
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
ATE391778T1 (de) Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69941791D1 (de) Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
AU2002305450A1 (en) Proteomimetic compounds and methods
EP0653940A4 (de) Glialmitogene faktoren, ihre herstellung und verwendung.
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
ATE182628T1 (de) Ein protein, das spezifische dna-strukturen erkennt, und seine verwendungen
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DK0714441T3 (da) Rekombinante Cladosporium herbarum allergener
WO2001025437A3 (en) Growth factor polypeptides and nucleic acids encoding same
ATE332923T1 (de) Cr1 fragmente und deren verwendung